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DISPATCHES
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Melioidosis is thought to be endemic, although underdiag-
nosed, in Africa. We identified 5 autochthonous cases of 
Burkholderia pseudomallei infection in a case series in Ke-
nya. Incidence of B. pseudomallei bacteremia in Kenya’s 
Kilifi County is low, at 1.5 cases per million person-years, 
but this result might be an underestimate.
Burkholderia pseudomallei, the causative agent of meli-oidosis, is a gram-negative bacillus endemic particu-
larly in northern Australia and South and Southeast Asia. 
Worldwide, B. pseudomallei causes ≈165,000 cases of 
disease and ≈89,000 deaths annually (1). The presence of 
B. pseudomallei in Africa has been demonstrated by spo-
radic cases of melioidosis reported in travelers returning 
from countries including Kenya (2). Indigenous culture-
confirmed cases have been reported in only 4 countries in 
Africa, mainly from research centers with diagnostic labo-
ratory facilities (3). 
The first case of melioidosis linked to Kenya was diag-
nosed in 1982 in a tourist from Denmark who had visited 
Nyali (an area of Mombasa City), ≈50 km south of the town 
of Kilifi (2). Follow-up clinical surveillance in Nairobi and 
environmental surveillance from other regions in Kenya 
yielded no B. pseudomallei isolates (4). However, grow-
ing concerns over possible underestimation of the disease 
in potentially endemic areas, including in tropical Africa, 
have led to calls for improved surveillance (5).
In 2010, at Kilifi County Hospital (KCH), we isolated 
B. pseudomallei from the blood culture of a 3-year-old 
child after a near-drowning accident in a seasonal river. 
The identity of the isolate was confirmed by real-time PCR 
targeting the type III secretion system genes of B. pseudo-
mallei (6), and the isolate was later sequenced for a study 
of geographic dissemination of B. pseudomallei (7). After 
this identification, we conducted a retrospective analysis of 
archived blood culture isolates collected during 1994–2012 
to investigate possible missed cases of invasive B. pseudo-
mallei infection. 
The Study
During 1994–1998, blood culture was performed on all 
febrile patients admitted to the pediatric wards at KCH. 
Since 1998, all pediatric patients <15 years of age admit-
ted, except those having trauma, burns, or elective surgery, 
have had blood samples drawn for culture. Surveillance for 
patients >15 years of age began in 2007; blood samples are 
drawn at admission for cultures on patients meeting clini-
cal criteria for possible invasive bacterial disease. Since 
2002, hospitalization events have been linked to the Kilifi 
Health and Demographic Surveillance System (KHDSS), 
which monitors the population of ≈280,000 over an area of 
891 km2 (8). Informed consent is obtained from all patients 
participating in the surveillance, including for storage of 
isolates and future use of clinical data.
Blood samples for bacterial cultures were collected in 
BACTEC Peds Plus or BACTEC Plus Aerobic/F bottles 
(Becton Dickinson, https://www.bd.com) and incubated 
on a BACTEC FX 9050 Automated Blood Culture instru-
ment (Becton Dickinson). Nonfastidious, oxidase-positive, 
gram-negative bacilli were identified by using API 20NE 
test kits (bioMérieux, https://www.biomerieux.com). We 
reviewed all gentamicin-resistant, glucose-nonfermenting, 
gram-negative rods, with the exception of Pseudomonas 
aeruginosa, even if the API 20NE identification was ac-
ceptable, to account for difficulties in speciating Burkhold-
eria spp. with biochemical methods.
A total of 86,582 patients <15 years of age were ad-
mitted during 1994–2012 and 18,864 patients ≥15 years 
of age during 2007–2012. Surveillance identified 33 gen-
tamicin-resistant, glucose-nonfermenting bacilli in 14,235 
positive blood cultures from patients <15 years of age 
and 5 gentamicin-resistant, glucose-nonfermenting bacilli 
in 705 positive blood cultures from patients ≥15 years of 
age (Figure). We retrieved all 38 isolates from storage for 
PCR, which we performed using published primer and 
probe sequences (6).
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We identified 4 isolates as B. pseudomallei by PCR, 
including the index isolate from 2010 (Table 1; Appendix, 
https://wwwnc.cdc.gov/EID/25/5/18-0545-App1.pdf). One 
isolate was previously identified as B. cepacia, and 2 were 
previously labeled as Pseudomonas species. We identified 
a fifth B. pseudomallei case in July 2014 in a 68-year-old 
female patient with diabetes mellitus and bilateral cervical 
abscesses (Table 1; Appendix). Blood culture results were 
negative, but aspirated pus grew B. pseudomallei, identi-
fied by API 20NE and confirmed by PCR. 
None of the case-patients had any history of travel out-
side Kilifi County. Three died during the course of their 
admission. No further information is available for the 2 
case-patients who survived because they were not residents 
of the area surveyed by KHDSS.
To estimate the incidence of melioidosis bloodstream 
infection, we divided the number of invasive B. pseudo-
mallei cases among KHDSS residents by the sum of the 
annual midyear population counts during 2002–2012 for 
those <15 years of age and during 2007–2012 for those 
>15 years of age. We also adjusted for the sensitivity of 
the surveillance to account for the proportion of patients 
not consenting to the surveillance study and those who 
did not have a blood culture drawn. For the period before 
2002, we extrapolated age-specific population estimates 
by using a log-linear model of age-specific population 
data based on subsequent enumerations. The estimated 
incidence was 1.3 cases/1 million person-years of obser-
vation for those <15 years of age and 2 cases/1 million 
person-years of observation for those ≥15 years of age 
(Table 2).
Conclusions
We identified 5 cases of melioidosis from a single sur-
veillance site in Kenya. Despite reports suggesting that 
melioidosis is endemic but underdetected in the region 
(5), we demonstrated low incidence in this part of Ke-
nya. Even so, B. pseudomallei has emerged as an under-
diagnosed cause of sepsis in Kilifi County. The empiri-
cal treatment used for sepsis, ampicillin and gentamicin, 
does not cover B. pseudomallei. The lack of patho-
genomonic clinical features makes it difficult to detect 
melioidosis clinically, especially in areas to which the 
disease is not endemic. In the series we report, 2 case-
patients died before receiving definitive treatment, and 
only 1 case-patient received antimicrobial drugs recom-
mended to treat melioidosis.
The integrated, population-based bacterial surveil-
lance system in Kilifi County provides a unique opportuni-
ty to estimate incidence. Routine blood culture sampling of 
all admitted patients <15 years of age and eligible patients 
>15 years of age eliminates reliance on clinical suspicion 
for bacteremic melioidosis. The use of molecular methods 
on isolates suspected to be B. pseudomallei will probably 
enhance case detection because B. pseudomallei is com-
monly misidentified or unidentified by culture (9). Only 
2 isolates in our study were identified by using standard 
techniques, despite the reported good discriminatory per-
formance of API 20NE in distinguishing B. pseudomallei 
and B. cepacia (10).
Our reported incidence rates might still be underes-
timated. Our data do not account for KHDSS residents 
who do not go to KCH. For example, ≈64% of deaths 
in children <5 years of age in the KHDSS area occur at 
home or in other healthcare facilities (8). Furthermore, as 
Figure. Identification of gentamicin-resistant, glucose-nonfermenting 
bacilli and Burkholderia pseudomallei from isolates collected from 
patients at Kilifi County Hospital, Kilifi, Kenya, 1994–2012.
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demonstrated by the fifth case, the incidence of nonbac-
teremic infection might be higher because non–blood 
culture samples are not systematically collected. Only 
50%–75% of patients with melioidosis are bacteremic 
(11), and culture has an estimated sensitivity of 60.2% 
for melioidosis (12). In addition, our screening method 
excluded gentamicin-susceptible isolates. If gentamicin-
susceptible B. pseudomallei is as common in Kenya as 
reported in other areas (13), additional surveillance that 
includes these organisms could increase the reported in-
cidence rates. Finally, melioidosis often is unevenly dis-
tributed within endemic areas, as noted in Thailand (14). 
Despite these factors, our results suggest that, although B. 
pseudomallei is present in tropical Africa, the incidence 
of invasive melioidosis is surprisingly low.
The differences in disease incidence in Africa and 
Asia are striking. Host factors, such as diabetes mellitus, 
might contribute, but environmental factors and agricul-
tural practices, such as rice farming, are probably more 
important in permitting exposure to and environmental 
persistence and proliferation of the organism. Nonethe-
less, Kenya has been identified as environmentally suit-
able for B. pseudomallei because of its soil type, agricul-
tural practices, and rainfall (1). Our study demonstrates 
the presence of B. pseudomallei in Kenya. Changes 
in climate and agricultural practices might lead to fu-
ture increases in melioidosis, and ongoing surveillance 
is necessary.
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Table 1. Clinical summary of patients with positive Burkholderia pseudomallei isolates, Kilifi, Kenya, 2002–2014* 
Year Age/sex Clinical features 
Risk 
factors Diagnosis† 
Culture 
source 
Antimicrobial sensitivity Days in 
hospital Outcome AMC STX TET CAZ IMI 
2002 8 d/M Fever, jaundice, 
respiratory 
distress 
None 
identified 
Neonatal sepsis Blood S S S S S 3 Died 
2008 7 d/M Respiratory 
distress 
None 
identified 
Severe 
pneumonia, 
neonatal sepsis 
Blood S S S S S 3 Survived 
2010 3 y/F Fever, 
respiratory 
distress 
Near-
drowning 
Severe 
pneumonia, 
septic shock 
Blood S S S S S 6 Died 
2011 52 y/M Persistent fever 
and night 
sweats of 
unknown 
duration 
None 
identified 
Acute renal 
failure, 
meningitis 
Blood S S S S S 5 Died 
2014 68 y/F Fever, bilateral 
cervical neck 
swellings 
Diabetes 
mellitus 
Diabetes, 
cervical 
lymphadenitis 
Pus swab S S S S S 40 Survived 
*AMC, amoxicillin/clavulanic acid; CAZ, ceftazidime; IMI, imipenem; S, susceptible; STX, sulfamethoxazole/trimethoprim; TET, tetracycline. 
†Diagnosis at time of admission. 
 
 
 
Table 2. Incidence of melioidosis in Kilifi County Hospital, Kilifi, Kenya, 1994–2012* 
Patient age group No. cases 
No. case-patients 
residing in KHDSS area Study period 
Person-years 
of observation 
Crude incidence† 
(95% CI) 
Adjusted incidence† 
(95% CI) 
<15 y 3 2 1994–2012 2,026,781 1.0 (0.12–3.56) 1.3 (0.17–5.17) 
≥15 y 1 1 2007–2012 782,373 1.3 (0.03–7.1) 2.0 (0.08–15.6) 
Overall 4 3 NA 2,809,154 1.1 (0.22–3.12) 1.5 (0.35–5.0) 
*KHDSS, Kilifi Health and Demographic Surveillance System; NA, not applicable. 
†Incidence per 106 person-years of observation, adjusted for nonconsenters and missing blood cultures among eligible consenters. 
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etymologia revisited
Burkholderia
[burk′′hol-dēr′e-ə]
This genus of gram-negative, rod-shaped bacteria comprising 
animal and plant pathogens was named for American plant 
pathologist Walter H. Burkholder. Dr. Burkholder first described a 
particular species of this genus, later called Burkholderia cepacia 
(Latin for “like onion”), after an outbreak of infection in vegetable 
growers in New York State in 1949. Previously known to cause 
disease in onion bulbs, these organisms are now recognized as 
major bacterial lung pathogens in patients with cystic fibrosis. 
B. mallei causes glanders in horses, and B. pseudomallei is 
the etiologic agent of melioidosis in humans and animals. Dr. 
Burkholder is recognized for helping establish the role of bacteria 
as plant pathogens.
Source:  Dorland’s illustrated medical dictionary, 31st edition. Philadelphia: 
Saunders; 2007; De Soyza A, Silipo A, Lanzetta R, Govan JR, Molinaro A.  
Chemical and biological features of Burkholderia cepacia complex 
lipopolysaccarides. Innate Immunity. 2008;14:127. 
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Appendix  
Case Summaries of Patients with Melioidosis, Kilifi, Kenya 
Patient 1. November 2002. An 8-day old male was admitted with a history of fever for 4 
days and yellowness of eyes for 3 days. Mother reported normal breastfeeding. On examination 
he was febrile (temperature 39.0°C) and tachypneic (respiratory rate 84 cycles/min). He was 
pale, capillary refill time was prolonged, he had jaundice, chest wall indrawing and nasal flaring. 
The hemogram showed leukocytosis comprising mainly neutrophils, blood slide for malaria 
parasites was negative. Blood culture showed gram-negative rods that were later identified as B. 
pseudomallei. There was no growth from the cerebral spinal fluid culture. The patient died after 
3 days of treatment in the ward. Records of antibiotic treatment were not available from the 
retrieved case record, but first line treatment for this condition in 2002 was penicillin and 
gentamicin (1). 
Patient 2. June 2008. A 7-day-old male child was first seen with fever and a history of 
difficulty breathing for 3 days. The child had been born at home and his mother reported normal 
breastfeeding. On examination he was in respiratory distress and had chest wall indrawing, and a 
diagnosis of neonatal sepsis was made. There was no growth from the cerebrospinal fluid 
culture. He was treated empirically with ampicillin and gentamicin, and by day 3 had improved 
sufficiently to be discharged. Subsequently, a gentamicin-resistant nonglucose-fermenting gram-
negative rod was isolated on day 5, which could not be identified further at that time. The child 
was not a resident of the KHDSS district, and no further follow-up information was available. 
Patient 3. May 2010. A 3-year-old female child was admitted with a history of cough, 
difficulty breathing, and fever after a near drowning accident in a local seasonal river. She had 
been found unconscious with a distended abdomen. She later regained full consciousness but was 
not brought for treatment until 2 days later, when she developed respiratory symptoms. At 
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admission, she had a temperature of 38.9°C and a respiratory rate of 50 cycles/min; she had nasal 
flaring and chest wall indrawing. The white cell count showed leukocytosis (18.2 × 109 cells/L) 
and neutrophilia (73%) on the differential count. Her chest radiograph had patchy opacities and 
oxygen saturation measured by oximetry was 96% on room air. She had features of severe 
pneumonia, and was initially treated with ampicillin and gentamicin, which was changed to 
ceftriaxone after 48 hours because there was no improvement in the clinical condition. On day 5, 
cloxacillin and metronidazole were added to the treatment. On day 5, admission blood cultures 
grew gram-negative rods, which were identified as Burkholderia pseudomallei (API 20NE 
profile 1156576), susceptible to ceftazidime but resistant to gentamicin. The patient died on day 
6 before any further changes to the treatment were effected. 
Patient 4. October 2011. A 52-year-old man was seen with an acute respiratory illness 
after persistent fever and night sweats. The duration of symptoms was not recorded in the patient 
records we retrieved. He was febrile (temperature 38.4°C) at admission, but no other constituent 
clinical signs were elicited. Blood counts and white cell differential counts also were within 
normal ranges. Sputum was negative for acid-fast bacilli on direct microscopy. He was initially 
treated with penicillin and gentamicin. A blood culture taken at admission became positive on 
day 5 for gram-negative rods that were susceptible to ceftazidime and imipenem. The final 
identity of the organism was not fully determined at the time. The patient deteriorated and died 
on day 5. We could not retrieve any results showing renal function tests or cerebrospinal fluid 
studies from the patient’s records although the discharge diagnosis on record was meningitis 
with acute renal failure. 
Patient 5. July 2014. A 68-year-old female patient, with insulin-dependent diabetes 
mellitus, was seen with bilateral cervical abscesses. She had attended outpatient clinics 2 weeks 
previously for investigation of cervical lymphadenopathy suspected to be tuberculous 
lymphadenitis. A fine needle aspirate had been performed, the results of which were not 
available on request. At admission, she had hyperglycemia and bilateral neck abscesses that were 
incised and drained. The complete blood count, liver and renal function tests were normal. The 
pus aspirate grew B. pseudomallei (API 20NE Profile 1156573); blood culture results were 
negative. Abdominal ultrasound done was normal. She was managed on intravenous imipenem 
for 10 days and discharged on co-trimoxazole for the eradication phase regimen to continue for 3 
 Page 3 of 3 
months. She did not return for the follow up clinic appointments. She was not a resident of the 
KHDSS and no further follow-up information was available. 
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